

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

CD223 (LAG-3)

RRID:AB_2742438

Type: Antibody

Proper Citation

BD Biosciences Cat# 744727, RRID:AB_2742438

Antibody Information

URL: http://antibodyregistry.org/AB_2742438

Proper Citation: BD Biosciences Cat# 744727, RRID:AB_2742438

Target Antigen: CD223 (LAG-3)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD223 (LAG-3)

Description: This monoclonal targets CD223 (LAG-3)

Target Organism: human

Clone ID: T47-530

Antibody ID: AB_2742438

Vendor: BD Biosciences

Catalog Number: 744727

Record Creation Time: 20250819T232127+0000

Record Last Update: 20250820T050528+0000

Ratings and Alerts

No rating or validation information has been found for CD223 (LAG-3).

No alerts have been found for CD223 (LAG-3).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Jassowicz L, et al. (2026) Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes. Cancer cell, 44(6), 1290.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T??cells. Cell reports methods, 3(1), 100388.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer cell, 40(9), 1010.

Sosa Cuevas E, et al. (2022) Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients. Clinical & translational immunology, 11(5), e1382.